Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 19/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
| ▸ | WNT1 | P04628 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CLK3 | P49761 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20622229 | 0.80 | GSK3B (0.36) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL21117175 | 0.77 | RIPK1 (0.48) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1780991 | 0.76 | CYP19A1 (0.66) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL1778505 | 0.76 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL16321934 | 0.71 | RIPK1 (0.62) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL26053438 | 0.71 | RIPK1 (0.71) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL25937022 | 0.71 | RIPK1 (0.54) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL18583291 | 0.71 | RIPK1 (0.42) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL30677000 | 0.70 | RIPK1 (0.52) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL14115574 | 0.70 | RIPK1 (1.00) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185531-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200289469-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185531-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | RIPK1 2142/4885CCNB2 4166/4885CDK1 3175/4885 |
| US-20200289469-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | RIPK1 2142/4885CCNB2 4166/4885CDK1 3175/4885 |
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | RIPK1 1743/4885CCNB2 1006/4885CDK1 248/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | RIPK1 3508/4885CCNB2 3307/4885CDK1 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.